Invention Grant
- Patent Title: Nanobody dimers linked via C-terminally engineered cysteins
-
Application No.: US15548830Application Date: 2016-02-05
-
Publication No.: US11021544B2Publication Date: 2021-06-01
- Inventor: Carlo Boutton , Daniel Janssen , Peter Casteels , Peter Schotte , Francis Descamps
- Applicant: Ablynx N.V.
- Applicant Address: BE Ghent-Zwijnaarde
- Assignee: Ablynx N.V.
- Current Assignee: Ablynx N.V.
- Current Assignee Address: BE Ghent-Zwijnaarde
- Agency: Wolf, Greenfield & Sacks, P.C.
- International Application: PCT/EP2016/052578 WO 20160205
- International Announcement: WO2016/124781 WO 20160811
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61K47/68 ; C07K16/00 ; A61K51/10 ; C07K16/18 ; A61P35/00 ; A61K38/07 ; A61K38/08 ; C07K16/24 ; C07K16/28

Abstract:
The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.
Public/Granted literature
- US20190100599A1 NANOBODY DIMERS LINKED VIA C-TERMINALLY ENGINEERED CYSTEINS Public/Granted day:2019-04-04
Information query